WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) have received an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.4118.

Several research firms have weighed in on WVE. Wall Street Zen upgraded WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Canaccord Genuity Group dropped their price target on WAVE Life Sciences from $52.00 to $43.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Wells Fargo & Company upped their price target on WAVE Life Sciences from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. New Street Research set a $13.00 price target on WAVE Life Sciences in a research note on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Monday, April 20th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG raised its holdings in WAVE Life Sciences by 1.5% during the 4th quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock valued at $1,627,000 after buying an additional 1,441 shares during the period. AlphaCentric Advisors LLC raised its holdings in WAVE Life Sciences by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 29,175 shares of the company’s stock valued at $212,000 after buying an additional 1,585 shares during the period. First Trust Advisors LP raised its holdings in WAVE Life Sciences by 15.7% during the 1st quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock valued at $98,000 after buying an additional 1,830 shares during the period. Smartleaf Asset Management LLC raised its holdings in WAVE Life Sciences by 645.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after buying an additional 1,942 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock valued at $138,000 after buying an additional 1,972 shares during the period. 89.73% of the stock is currently owned by institutional investors.

WAVE Life Sciences Stock Performance

Shares of NASDAQ:WVE opened at $6.16 on Friday. The stock has a 50 day moving average of $6.64 and a 200 day moving average of $10.94. The company has a market cap of $1.19 billion, a PE ratio of -5.81 and a beta of -1.33. WAVE Life Sciences has a 12-month low of $5.02 and a 12-month high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21. The company had revenue of $38.25 million during the quarter, compared to the consensus estimate of $8.45 million. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%. Equities research analysts predict that WAVE Life Sciences will post -1.1 earnings per share for the current fiscal year.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.